Zipalertinib plus chemotherapy extends survival in EGFR exon 20 lung cancer
In the phase 3 REZILIENT 3 trial, adding zipalertinib to platinum-pemetrexed chemotherapy extended median progression-free survival from 8.5 to 14.5 ...
Tag: zipalertinib
POPULAR NEWS
-
AI Generates Rare Gut Lesion Images From a Single Photo to Sharpen Diagnostics
-
Zipalertinib plus chemotherapy extends survival in EGFR exon 20 lung cancer
-
Copper-Doped Bioactive Glass Ointment Speeds Wound Healing in Metabolic Syndrome
-
Drone-mounted multispectral sensors outpredict handheld NDVI for wheat yield